C374 Coris 01

Identification of OXA-23 carbapenem-resistant Acinetobacter spp.

The global spread of carbapenemresistant Acinetobacter spp., and particularly A. baumannii, in healthcare settings causes a major threat to patient survival. Worldwide, drug-resistant Acinetobacter spp. are responsible for serious nosocomial outbreaks, mostly in intensive care units. Even though different resistance mechanisms have been described, production of Amber Class D oxacillinases OXA-23-like hydrolysis enzymes is the most frequently acquired mechanism. Fast and accurate detection of OXA-23-producing strains remains challenging at the laboratory level. Specific identification of oxacillinase-expressing Acinetobacter requires genotypic molecular assays that remain expensive and not commercially available. However immunochromatography lateral flow tests are cost-effective and convenient to detect drug-hydrolysing enzymes. Today, a large panel of lateral flow tests to detect carbapenemase-expressing Enterobacteriacea, named “RESIST”, is commercialized by the Belgian company Coris BioConcept. In order to fulfill the unmet need for fast and reliable detection of drugresistant Acinetobacter, Coris BioConcept developed a new lateral flow assay, “OXA- 23 K-SeT”, for the specific identification of OXA-23-mediated carbapenem-resistant in Acinetobacter spp. from a single colony. With results available in less than 15 minutes, this easy-to-use and instrument-free rapid test represents the first phenotypic, specific and non-molecular confirmatory assay for OXA-23 detection. It will expand the RESIST range of products already adopted nowadays by routine and reference laboratories worldwide, offering an additional tool to ensure the successful treatment of patients and to prevent the spread of carbapenemase-producing bacteria in healthcare settings.

Supplier: Coris Bioconcept

Mail the supplier